Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Liver Institute

Neither a doctor nor a teaching hospital

Research payments

$4,595,641

49 payments

Through program year 2025, Texas Liver Institute is reported as receiving $4,595,641 in research payments, across 49 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $369,105 7
2024 Research $733,109 7
2023 Research $956,606 18
2022 Research $2,114,272 9
2021 Research $39,833 4
2020 Research $315,922 2
2019 Research $66,796 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,362,168 8 payments
  2. Deciphera Pharmaceuticals Inc. $1,327,995 17 payments
  3. Vertex Pharmaceuticals Incorporated $380,983 1 payment
  4. Kadmon Corporation LLC $241,397 1 payment
  5. Boehringer Ingelheim International GmbH $191,972 3 payments
  6. Amgen Inc. $74,210 7 payments
  7. E.R. Squibb & Sons, L.L.C. $8,993 8 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $4,526 3 payments
  9. Boehringer Ingelheim RCV GmbH & Co KG $3,396 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Single Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Iptacopan (Lnp023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function $1,647,064 1 payment
  2. A Phase 1, Open-label Study of the Pharmacokinetics, Safety, and Tolerability of Single-dose Vimseltinib in Participants with Hepatic Impairment Compared to Healthy Control Participants $1,327,995 17 payments
  3. A Phase 1, Open-Label, Single-Dose, Multi-Center, Parallel Group Study to Evaluate the Pharmacokinetics of Jdq443 in Participants With Mild, Moderate Or Severe Hepatic Impairment Compared to Matched Healthy Control Participants. $562,144 4 payments
  4. A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects $380,983 1 payment
  5. A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment $241,397 1 payment
  6. MRD PoCP study in NFLD 12 wks $182,674 2 payments
  7. A Randomized Double Blind Multicenter Study to Assess the Safety Tolerability and Efficacy of A Combination Treatment of Tropifexor Ljn452 and Cenicriviroc CVC in Adult Patients With Nonalcoholic Steatohepatitis Nash and Liver Fibrosis $152,960 3 payments
  8. Ph1 FIH to Evaluate Safety; PK & PD $42,553 2 payments
  9. AMG 609_ Ph1 Study To Evalulate Safety; PK and PD in AMG 609 $19,001 2 payments
  10. Hepatic Impairment Study $10,337 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record